Ebselen in acute middle cerebral artery occlusion: A placebo-controlled, double-blind clinical trial

Cerebrovascular Diseases

Volumn 9, Issue 2, 1999, Pages 112-118

  Ogawa, Akira ^a   Yoshimoto, Takashi ^b   Kikuchi, Haruhiko ^c   Sano, Keiji ^d   Saito, Isamu ^e   Yamaguchi, Takenori ^c   Yasuhara, Hajime ^f  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d Fuji Brain Institute and Hospital   (Japan)

^e KYORIN UNIVERSITY   (Japan)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Ebselen; Middle cerebral artery occlusion; Neuroprotection; Randomized controlled trial

Indexed keywords

EBSELEN; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RESPIRATORY TRACT INFECTION;

AGED; ANTIOXIDANTS; ARTERIAL OCCLUSIVE DISEASES; AZOLES; CEREBRAL ARTERIES; CEREBRAL INFARCTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOSELENIUM COMPOUNDS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0033042957     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000015908     Document Type: Article

References (17)

1. Müller A, Cadenas E, Graf P, Sies H: A novel biologically active selenoorganic compound-I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ51 (ebselen). Biochem Pharmacol 1984;33:3235-3239.
2. Siesjo BK: Pathophysiology and treatment of focal cerebral ischemia. Part II. Mechanisms of damage and treatment. J Neurosurg 1992;77: 337-354.
3. Zini I, Tomasi A, Grimaldi R, Vannini V, Agnati LF: Detection of free radicals during brain ischemia and reperfusion by spin trapping and microdialysis. Neurosci Lett 1992; 138:279-282.
4. Johshita H, Sasaki T, Matsui T, Hanamura T, Masayasu H, Asano T, Takakura K: Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats. Acta Neurochir 1990;51:239-241.
5. Dawson DA, Masayasu H, Graham DI, Macrae IM: The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci Lett 1995; 185: 65-69.
6. Saito I, Asano T, Sano K, Takakura K, Abe H, Yoshimoto T, Kikuchi H, Ohta T, Ishibashi S: Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurologic deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 1998;42:269-278.
7. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, Yasuhara H: Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Stroke 1998;29:12-17.
8. Takasago T, Peters EE, Graham DI, Masayasu H, Macrae IM: Neuroprotective efficacy of ebselen, and anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br J Pharmacol 1997;122:1251-1256.
9. Russ JC: The Image Processing Handbook, ed 2. Boca Raton, CRC Press, 1994.
10. Jennett B, Bond M: Assessment of outcome after severe brain damage. A practical scale. Lancet 1975;i:480-484.
11. Gelmers HJ, Gorter K, Weerdt CJ, Wiezer HJA: A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203-207.
12. Maiorino M, Roveri A, Coassin M, Ursini F: Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51). Biochem Pharmacol 1988;37:2267-2271.
13. Safayhi H, Tiegs G, Wendel A: A novel biologically active seleno-organic compound - V. Inhibition by ebselen (PZ51) of rat peritoneal neutrophil lipoxygenase. Biochem Pharmacol 1985;34:2691-2694.
14. Ichikawa S, Omura K, Katayama T, Okamura N, Ohtsuka T, Ishibashi S, Masayasu H: Inhibition of Superoxide anion production in guinea pig polymorphonuclear leukocytes by a selenoorganic compound, ebselen. J Pharmacobiodyn 1987; 10:595-597.
15. Hattori R, Inoue R, Sase K, Eizawa H, Kosuga K, Aoyama T, Masayasu H, Kawai C, Sasayama S, Yui Y: Preferential inhibition of inducible nitric oxide synthase by ebselen. Eur J Pharmacol 1994;267:R1-R2.
16. Masumoto H, Sies H: The reaction of ebselen with peroxynitrite. Chem Res Toxicol 1996;9: 262-267.
17. Nozawa R, Arai M, Kuruto R, Motohashi T, Masayasu H: Susceptibility of mice to bacterial and fungal infections after intragastric administration of ebselen. J Pharm Pharmacol 1996; 48:64-67.